Merus had its Relative Strength (RS) Rating upgraded from 67 to 73 Tuesday — a welcome improvement, but still shy of the 80 or better score you look for.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the top-performing stocks often have an 80 or higher RS Rating as they begin their largest price moves. See if Merus can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Merus is not currently showing a potential entry point. See if the stock goes on to build a sound pattern that could kick off a new price move.
Merus reported 0% earnings growth in the latest quarterly report, while sales growth came in at 2%.
Merus holds the No. 152 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Krystal Biotech and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
